Paraplatin - Carboplatin

Paraplatin (Carboplatin) Current Status and Future Prospects (Eds. S. K. Carter and K. Heilman) Cancer Treatment Rev. 12, Supplement A (1985). 

The platinum(IV) compound that has shown most promise is carboplatin (paraplatin), which received FDA approval in 1990. Features to note in its structure are the use of hydroxy and carboxylate groups to improve water solubility. As noted above, the ammine ligand has been found to need at least one hydrogen, possibly for hydrogen-bonding to phosphate groups in the DNA (Figure 3.116). 

Of the wide array of platinum derivatives, carboplatin is the only compound except cisplatin that is used in medical practice, and it differs from cisplatin in the replacement of two chlorine atoms with a cyclobutan-l,l-dicarboxylic acid fragment. Like cisplatin, carboplatin also reacts with DNA to form both internal and external cross-bonds. The range and indications of use are practically analogous to cisplatin. Synonyms of this drug are paraplatin and others. 

Carboplatin (Paraplatin) is an analogue of cisplatin. Its plasma half-life is 3 to 5 hours, and it has no significant protein binding. Renal excretion is the major route of drug elimination. 

Carboplatin [Paraplatin] Carcinoma of the ovaries Blood disorders [anemia, leukopenia, neutropenia, thrombocytopenia] unusual tiredness Gl distress [nausea, vomiting]... 

Carboplatin Paraplatin - Bristol-Myers Squibb Oncology)... 

Carboplatin (Paraplatin) Ovarian cancer NSCLC SCLC head and neck cancer testicular cancer bladder cancer breast... 

Another organometallic platinum drug has been approved in the United States. It is a diammin platinum coordinate with 1,1-cyclobutanedicarboxylic acid named carboplatin (CBDA, Paraplatin). Its advantages over cisplatin are a lesser emetogenic effect as well as a possible decrease in nephro- and ototoxicity. 

Carboplatin (paraplatin) is administered as an intravenous infusion over at least 15 minutes and is given once every 28 days. Carboplatin currently is U.S. Food and Drug Administration (FDA)-approved for use in combination with paclitaxel or cyclophosphamide in patients with advanced ovarian cancer and lung cancer. 

Carboplatin Paraplatin Carboplat Erbakar Nonoplat Platinum-based anticancer agent Treatment of ovarian cancer ... 

---